LGALS3 and type 2 diabetes mellitus: Yet, Galectin-3 and Pentraxin-3 showed an upward trend in patients with T2DM, and especially in those with both T2DM and HFpEF, supporting the hypothesis by Paulus and Tschöpe that inflammatory and pro-fibrotic pathways may contribute to HFpEF progression in these patients [7].